Skip to main content
. Author manuscript; available in PMC: 2011 May 27.
Published in final edited form as: Cancer Prev Res (Phila). 2009 Apr 28;2(5):440–449. doi: 10.1158/1940-6207.CAPR-08-0136

Table 6.

Change in Ki67

Observation Treated Difference* (treated – observed)
Difference 95% CI P
All subjects
n 17 32
 Maximum −5.14 (34.55) −8.09 (33.04) −1.48 (−18.24 to 15.29) 0.86
 Average 5.63 (21.22) −1.68 (19.20) −4.69 (−15.94 to 6.57) 0.41
 Ki67 fraction 0.04 (0.40) 0.03 (0.38) −0.02 (−0.23 to 0.20) 0.88
Current smokers
n 9 14
 Maximum −10.00 (36.92) −13.77 (38.83) 3.58 (−22.47 to 29.62) 0.78
 Average 5.31 (27.29) −1.63 (22.54) −3.54 (−23.64 to 16.56) 0.72
 Ki67 Fraction −0.01 (0.49) 0.07 (0.38) 0.04 (−0.32 to 0.40) 0.81
Former smokers
n 8 18
 Maximum 0.34 (33.27) −3.67 (28.12) −3.93 (−26.28 to 18.42) 0.72
 Average 5.99 (13.31) −1.73 (16.84) −5.76 (−18.87 to 7.35)
 Ki67 fraction 0.09 (0.30) −0.01 (0.38) −0.08 (−0.36 to 0.20) 0.57
*

Adjusted for baseline Ki67 level (either maximum, average, or fraction) “All subject” analysis is also adjusted for smoking status. Ki67 fraction is proportion of all samples within the individuals in which the Ki67 percentage exceeds 15%.